Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Mainolfi Nello

Goodman Noah

Jacobs Bruce N.

Kymera Therapeutics CEO Nello Mainolfi sold 50,000 shares for $6 million on July 7, 2026, following a 170% stock surge over 12 months. The sale involved exercising options at $2.08 and selling at $119 per share under a pre-scheduled Rule 10b5-1 trading plan. Despite the sale, Mainolfi retains 666,568 shares worth $79.5 million and 90,000 options, indicating continued confidence in the company's pipeline, particularly KT-621 in Phase 2b trials with FDA Fast Track status.

Kymera's CEO Sold $6 Million in Stock After a 170% Run

I have seen the stock market change people's lives! It can change yours too. Never Give Up! You may find my best stock ideas at: https://t.co/rqfRosoA4A

Kymera Therapeutics Inc (KYMR) Stock Price, Analysis & Trade Signals